Myricitrin (100 mg)

Myricitrin (100 mg)
 

• CAT Number : FNK-NS540103
• CAS Number : 17912-87-7   
• Molecular Weight : 464.38
• Molecular Formula : C₂₁H₂₀O₁₂
• Pack size: 100 mg
• Store: –20 ℃ 
• Purity: >99%(HPLC)

Product Description
Myricitrin is a flavonoid glycoside found naturally in various plants. It is a 100 mg research-grade compound typically used for scientific studies investigating its biological activities and potential health benefits.

Property

• Chemical Formula: C₂₁H₂₀O₁₂
• Molecular Weight: 464.38 g/mol
• Appearance: Likely a pale yellow to off-white crystalline powder
• Solubility: Soluble in polar organic solvents, poorly soluble in water

Application and Usage

• Research: Used in studies investigating its antioxidant and anti-inflammatory properties
• Pharmaceutical Development: Investigated for potential therapeutic applications
• Analytical Standard: May be used as a reference compound in plant extract analysis
• Biochemical Studies: Used to study flavonoid metabolism and bioactivity

Safety and Handling

• Storage: Store in a cool, dry place, protected from light
• Handling: Use appropriate personal protective equipment, including gloves and eye protection
• Safety Measures: For research use only; not for human consumption without proper testing and approval

Involved Human Diseases

• Cardiovascular Diseases
  • Myricitrin exhibits cardioprotective properties that may help prevent and manage cardiovascular diseases:
    • It reduces oxidative stress and inflammation, which are key factors in the development of heart disease.
    • Myricitrin improves lipid profiles by lowering LDL cholesterol and increasing HDL cholesterol levels, reducing the risk of atherosclerosis.
    • It enhances endothelial function, which can help lower blood pressure and improve overall vascular health.
• Diabetes
  • Myricitrin shows potential in managing diabetes and its complications:
    • It improves insulin sensitivity by activating the AMP-activated protein kinase (AMPK) pathway.
    • Myricitrin inhibits enzymes like α-glucosidase and α-amylase, slowing down glucose absorption from the digestive system.
    • It protects pancreatic beta cells from oxidative stress, supporting overall insulin function and glucose management.
• Neurodegenerative Diseases
  • Myricitrin demonstrates neuroprotective effects that may be beneficial in treating neurodegenerative disorders:
    • It inhibits the aggregation of amyloid proteins, which is associated with Alzheimer's disease.
    • Myricitrin protects against oxidative stress and inflammation in the brain, potentially slowing the progression of neurodegenerative diseases.
    • It has shown promise in treating post-ischemic brain neurodegeneration and dementia.
• Cancer
  • Myricitrin exhibits anticancer properties through various mechanisms:
    • It acts as an antioxidant, neutralizing free radicals that can damage cellular DNA and promote cancer growth.
    • Myricitrin inhibits cancer cell growth by disrupting signaling pathways like PI3K/Akt and MAPK.
    • It induces apoptosis (programmed cell death) in cancer cells and suppresses angiogenesis, the formation of new blood vessels that feed tumors.
• Inflammatory Disorders
  • Myricitrin's anti-inflammatory effects may help in managing various inflammatory conditions:
    • It inhibits the production of pro-inflammatory chemicals like prostaglandins and leukotrienes.
    • Myricitrin modulates nuclear factor-kappa B (NF-κB), a key transcription factor in inflammation.
    • It shows potential in treating chronic inflammatory disorders such as rheumatoid arthritis and atopic dermatitis.
• Liver Diseases
  • Myricitrin demonstrates hepatoprotective properties:
    • It attenuates oxidative stress in liver cells.
    • Myricitrin regulates the inflammatory response through the AMPK/SREBP-1c pathway in liver cells.

Cell Signaling Pathways Affected

• PI3K/Akt/mTOR Pathway
  • Myricetin exhibits a dual effect on the PI3K/Akt pathway:
    • In healthy tissues, it promotes signaling through the Akt pathway to induce cytoprotection.
    • In cancer cells, it suppresses this signaling cascade to induce apoptosis.

• MAPK Pathway
  • Myricetin modulates the Raf/MEK/ERK cascade:
    • It binds to Raf in an ATP-noncompetitive manner, halting its activity.
    • It disrupts the kinase activity of MEK1 and suppresses ERK phosphorylation.
    • Myricetin reduces p38-MAPK protein levels.
• NF-κB Pathway
  • Myricetin inhibits the NF-κB pathway:
    • It suppresses NF-κB activation by halting the phosphorylation of Akt or ERK1/2.
    • Myricetin reduces protein levels of phosphorylated IKKα and IκBα.
• JAK/STAT Pathway
  • Myricetin interacts with and inhibits JAK1, consequently attenuating the phosphorylation-activation of STAT3. It also targets STAT1 in certain conditions.
• Nrf2 Pathway
  • Contrary to its inhibitory effects on other pathways, myricetin promotes the Nrf2 pathway:
    • It prevents Nrf2 ubiquitination-mediated destruction.
    • Myricetin mediates Nrf2 translocation to the nucleus, leading to activation of ARE and up-regulation of associated genes.
• TGFβ/Smad Pathway
  • Myricetin induces signaling through the TGFβ/Smad cascade. It targets TGFβ1 expression in certain conditions and can up-regulate TGFβ expression.
• Wnt/β-catenin Pathway
  • Myricetin modulates the canonical Wnt pathway:
    • It alters the phosphorylation status of β-catenin and GSK-3β.
    • In breast carcinoma cells, myricetin promotes dephosphorylation of GSK-3β through inhibiting PAK1 protein expression.
• Apoptotic Pathways
  • Myricetin influences apoptotic pathways:
    • It promotes intrinsic apoptosis by directly enhancing Bax expression and mitochondrial translocation.
    • In healthy cells, it activates PI3K/Akt signaling and inhibits ERK/JNK pathway to induce cytoprotection.